India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations 
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist 
Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
